MarketCapExport financials
Mesoblast Limited (MESO)
The export includes the complete available history of financial statements and ratios. Numbers are provided in full, without million or billion abbreviations, in their original reporting units.
CSV downloads as a ZIP archive with one file for each report and frequency.
Facebook
X
Telegram
Mesoblast Limited Cash Flow 2025-2011 | MESO
Brief overview of Mesoblast Limited's cash flow quality
The review uses the five latest available annual reports between 2021 and 2025.
The latest year produced an operating outflow of -$50 million. A return to positive cash generation is important.
Only 0 of five annual observations were positive, indicating weak repeatability.
What the cash flows show
Mesoblast Limited does not yet show sustainable internal cash generation. Stronger OCF and a return to free cash flow are needed.
Annual Cash Flow Mesoblast Limited
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Operating Cash Flow |
-50 M | -48.5 M | -63.3 M | -65.8 M | -101 M | -50.4 M | -57.8 M | -75 M | -95.5 M | -88 M | - | - | - | - | - |
Accounts Receivables |
- | - | - | - | - | - | 1 K | 11 K | - | - | - | - | - | - | - |
Annual performance
Select metrics to display
All numbers in USD currency
Quarterly Cash Flow Mesoblast Limited
| 2025-Q4 | 2025-Q2 | 2024-Q4 | 2024-Q2 | 2023-Q4 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Operating Cash Flow |
-30.3 M | -50 M | -20.7 M | -48.5 M | -26.6 M | -63.3 M | -47 M | - | - | - | - | - | -19.6 M | - | - | - | -28.2 M | - | - | - | -15.6 M | - | - | - | -19.5 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Accounts Receivables |
- | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 1 K | 1 K | 4 K | 1 K | 7 K | 2 K | - | 11 K | - | - | - | 12 K | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Quarterly performance
Select metrics to display
All numbers in USD currency
Cash Flow Statement is one of the three key financial reports of the company Mesoblast Limited, reflecting the actual cash inflows and outflows over a certain period. Unlike the income statement, which shows revenues and expenses on an accrual basis, the cash flow statement focuses on real cash flows — how much cash actually came into the company and how much was spent.
Main Sections of the Cash Flow Statement- Operating Activities
This section reflects cash flows related to the company’s core operations: receipts from sales of goods and services, payments to suppliers, employee salaries, taxes, and other operating expenses. Positive cash flow from operating activities indicates the viability of the business and its ability to generate cash. - Investing Activities
Shows cash movements related to the purchase and sale of long-term assets such as real estate, equipment, and investments in other companies. Negative cash flow here often indicates investments in growth, which can be a positive sign. - Financing Activities
Reflects the inflow and outflow of cash related to raising and repaying capital: issuing shares, loans, dividend payments, and loan repayments. This section shows how the company finances its activities and distributes profits.
The cash flow statement is important for investors because it allows them to assess the company’s real liquidity, showing whether it has enough cash to cover current obligations and investments — this is critical for financial stability. Additionally, it helps analyze the quality of earnings, since profits reported in the income statement can be "paper" profits and may not reflect actual cash inflows; the cash flow statement reveals this difference. The presence of free cash is also crucial for evaluating the company’s ability to finance growth and pay dividends, which is important for investors. Attention should also be paid to prolonged negative cash flows from operating activities, as this may serve as a warning sign of potential problems with the core business.
Cash flow statements of other stocks in the Biotechnology sector
| Issuer | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|
 |
Pfizer
PFE
|
$ 29.58 | 0.54 % | $ 168 B |  USA |
 |
Supernus Pharmaceuticals
SUPN
|
$ 37.88 | 0.5 % | $ 2.14 B | USA |
 |
Takeda Pharmaceutical Company Limited
TAK
|
$ 19.67 | 1.08 % | $ 31.1 B |  Japan |
 |
Revolution Medicines
RVMD
|
$ 177.96 | 0.22 % | $ 33.8 B | USA |
 |
Rhythm Pharmaceuticals
RYTM
|
$ 86.17 | 0.6 % | $ 5.6 B | USA |
 |
Prelude Therapeutics Incorporated
PRLD
|
$ 3.26 | 0.9 % | $ 251 M | USA |
 |
Sana Biotechnology
SANA
|
$ 2.27 | 6.22 % | $ 575 M | USA |
 |
Pulmatrix
PULM
|
$ 1.36 | 4.61 % | $ 4.97 B | USA |
 |
Zoetis
ZTS
|
$ 79.38 | 1.22 % | $ 35.2 B | USA |
 |
Ultragenyx Pharmaceutical
RARE
|
$ 14.54 | 1.81 % | $ 1.43 B | USA |
 |
XTL Biopharmaceuticals Ltd.
XTLB
|
$ 1.96 | 2.62 % | $ 1.32 B |  Israel |
 |
Zymeworks
ZYME
|
$ 25.03 | 0.16 % | $ 1.29 B |  Canada |
 |
AC Immune SA
ACIU
|
$ 2.39 | 2.08 % | $ 241 M |  Schweiz |
 |
Adagene
ADAG
|
$ 2.06 | 4.8 % | $ 122 M |  China |
 |
Adial Pharmaceuticals
ADIL
|
$ 3.49 | 11.15 % | $ 2.33 M | USA |
 |
ADC Therapeutics SA
ADCT
|
$ 1.4 | 0.34 % | $ 178 M | Schweiz |
 |
ADMA Biologics
ADMA
|
$ 10.68 | 3.77 % | $ 2.55 B | USA |
 |
Assembly Biosciences
ASMB
|
$ 20.09 | 0.19 % | $ 225 M | USA |
 |
Allogene Therapeutics
ALLO
|
$ 1.31 | 3.08 % | $ 289 M | USA |
 |
Amgen
AMGN
|
$ 432.49 | 0.08 % | $ 233 B | USA |
 |
Ardelyx
ARDX
|
$ 3.09 | 2.51 % | $ 745 M | USA |
 |
Armata Pharmaceuticals
ARMP
|
$ 3.37 | 9.06 % | $ 122 M | USA |
 |
Artelo Biosciences
ARTL
|
$ 2.7 | 0.36 % | $ 511 K | USA |
 |
Bicycle Therapeutics plc
BCYC
|
$ 3.46 | 2.56 % | $ 240 M |  Britain |
 |
Beam Therapeutics
BEAM
|
$ 23.47 | 4.57 % | $ 2.32 B | USA |
 |
Benitec Biopharma
BNTC
|
$ 8.11 | 2.05 % | $ 378 M | USA |
 |
BioNTech SE
BNTX
|
$ 87.71 | 1.74 % | $ 21.2 B |  Germany |
 |
ANI Pharmaceuticals
ANIP
|
$ 72.29 | 0.01 % | $ 1.45 B | USA |
 |
C4 Therapeutics
CCCC
|
$ 2.77 | 0.36 % | $ 230 M | USA |
 |
Cerus Corporation
CERS
|
$ 2.18 | 0.66 % | $ 415 M | USA |
 |
Certara
CERT
|
$ 9.37 | 0.26 % | $ 1.5 B | USA |
 |
Coherus BioSciences
CHRS
|
$ 0.99 | 1.9 % | $ 116 M | USA |
 |
Corcept Therapeutics Incorporated
CORT
|
$ 110.16 | 0.47 % | $ 11.4 B | USA |
 |
CorMedix
CRMD
|
$ 7.26 | 0.95 % | $ 523 K | USA |
 |
CRISPR Therapeutics AG
CRSP
|
$ 49.25 | 2.59 % | $ 4.43 B | Schweiz |
 |
Greenwich LifeSciences
GLSI
|
$ 14.55 | 1.48 % | $ 197 M | USA |
 |
Champions Oncology
CSBR
|
$ 4.7 | 0.94 % | $ 65 M | USA |
 |
Cue Biopharma
CUE
|
$ 16.71 | 0.38 % | $ 1.58 B | USA |
 |
DBV Technologies S.A.
DBVT
|
$ 9.05 | 2.71 % | $ 1.26 B |  France |
 |
Alterity Therapeutics Limited
ATHE
|
$ 2.62 | 8.64 % | $ 16.8 B |  Australia |
 |
Actinium Pharmaceuticals
ATNM
|
$ 1.13 | 6.6 % | $ 35.3 M | USA |